HOTH Hoth Therapeutics Inc.

1.38
-0.07  -5%
Previous Close 1.45
Open 1.44
52 Week Low 1.2663
52 Week High 3.5
Market Cap $32,942,906
Shares 23,871,671
Float 22,971,044
Enterprise Value $10,440,433
Volume 771,125
Av. Daily Volume 1,003,320
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
BioLexa
Atopic Dermatitis
Phase 1b
Phase 1b
Phase 1b cohort one safety objective met - June 28, 2021. Cohort 2 to commence screening September 2021.

Latest News

  1. NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.

    The goal of the study is to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and to determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease.  Hoth study will also determine if behavior is improved utilizing HT-ALZ in blocking NK-1Rs. To evaluate other forms of memory, we will also determine if chronic HT-ALZ treatment influences non-spatial memory using a novel object recognition and novel object location task. These tests will give us the ability to assess both hippocampal and non-hippocampal dependent memory. Additionally, these tests do not require food or water deprivation to motivate the animals, which may interfere with drug delivery or dosing regulation over time.

    The designed studies are taking place under a Scientific Research Agreement entered by Hoth as of June of this year.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.  To learn more, please visit https://ir.hoththerapeutics.com/

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Media Relations Contact: 

    Makovsky

    Email: 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-initiates-preclinical-study-of-ht-alz-for-alzheimers-disease-301345766.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  2. NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that a the Company's Scientific Co-Founder, Dr. Mark C. Poznansky's guest essay titled "The Vaccines We Have Are Good. But They Could Be So Much Better", was published in the New York Times on June 10, 2021.

    Dr. Mark C. Poznansky serves as Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky also serves as a scientific founder for Voltron Therapeutics, helping to advise on the early clinical research and implementation of testing in the clinical setting among other things.

    In the essay, Dr. Poznansky and his colleague Dr…

    NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that a the Company's Scientific Co-Founder, Dr. Mark C. Poznansky's guest essay titled "The Vaccines We Have Are Good. But They Could Be So Much Better", was published in the New York Times on June 10, 2021.

    Dr. Mark C. Poznansky serves as Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky also serves as a scientific founder for Voltron Therapeutics, helping to advise on the early clinical research and implementation of testing in the clinical setting among other things.

    In the essay, Dr. Poznansky and his colleague Dr. Michael V. Callahan discuss the impressive, ongoing efforts to get a safe, effective vaccine broadly into the population, as well as the remaining need for new vaccines that address the evolution of variants that can overcome the immunity provided by existing COVID-19 vaccines and/or prior infections.

    As a Scientific Co-Founder of Voltron Therapeutics, Dr. Poznansky has been instrumental in the development of HaloVax™, a Self-Assembling Vaccine (SAV) against COVID-19. HaloVax may not only prevent disease, but may offer safe administration with a strong, broad immune response, specifically designed to be applicable to emerging viral targets, such as COVID-19 and it's variants. Importantly, HaloVax™ is designed with safety as its top priority to avoid known vaccine adverse effects, including excessive local response or inappropriate immune response. Other vaccine approaches, in many cases, simply provoke the immune system to target an aspect of the COVID-19 virus, namely the spike protein, and then only as it appeared in the original pandemic outbreak in 2019. HaloVax is a flexible system for evoking a broad range of immune responses against a virus – simultaneously training the immune system to target several proteins contained with the virus that can be readily modified to rapidly address newly evolving variants. The need for second generation vaccine platforms like HaloVax is increasing, given the rise of the Delta variant and the inevitable rise of further variants that are evolving to evade the first-generation vaccines.

    The vaccine is built on a base of a heat shock protein (HSP70)-Avidin fusion protein that activates the cellular component of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of virus targeting peptides derived from our understanding of the COVID-19 structure, which are bound to the heat shock protein via Biotin. This enables rapid iteration and up-to-date, data informed, changes in the peptide sequences to enable swift production and accommodate potential changes in the pathogen itself. The selected immunogenic peptides complete the customized COVID-19 vaccine.

    Voltron Therapeutics previously announced positive data from its second set of preclinical animal testing of its COVID-19 vaccine. This study investigated an updated peptide construct, based on initial testing as well as recent scientific developments, in order to identify the best balance of immune responses for prevention of this pandemic pathogen.

    The study consisted of a full near GLP preclinical mouse study evaluating whether the self- assembling vaccine, consisting of the immune activating MTBhsp70-Avidin component and antigen targeting biotinylated immunogenic peptides, increased the immune response relative to controls or peptides alone.

    Results demonstrated that the self-assembling vaccine construct did indeed significantly increase both helper and cytotoxic T cell responses to the vaccine targeted antigens compared to controls. This proof of concept for the SAV platform is critical to the COVID-19 program, additional infectious disease targets as well as the oncology applications of this cutting-edge technology. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc (NASDAQ:HOTH).

    "We remain optimistic that our recent successful preclinical testing will rapidly lead to clinical trials in humans and bring us closer to a safe, broad acting, effective, and durable vaccine to help prevent disease caused by COVID-19 and future variants. Our discovery and operating teams have placed us on the cutting edge of vaccine development, leveraging our platform technology to create vaccines in a more rapid and adaptable manner," said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc.

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information please visit www.voltrontx.com.

    About HaloVax™, LLC

    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com.

    About Hoth Therapeutics, Inc.



    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contacts:



    Matt Duffy

    President

    Voltron Therapeutics, Inc.

    646-335-5923

    Jason Assad

    Voltron Therapeutics, Inc.

    Investor Relations

    678-570-6791



    Primary Logo

    View Full Article Hide Full Article
  3. NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology. The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.

    HT-003 is a group of retinoic acid metabolism blocking agents (RAMBA), which are novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.

    As part of the study, mouse skin was topically pre-treated with RAMBA or a non-clinical vehicle for two days. Then, the skin was intradermally injected peptidoglycan (PGN), which induces acne-like inflammation. The models demonstrated that PGN-induction of TLR2 and a broad list of inflammatory cytokines were inhibited in skin pre-treated with RAMBA.

    "The results of this study are extremely promising and suggests that this drug could both treat acne and may actually help prevent it," said Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, who is lead on the study. "The data also suggests that the HT-003 compounds have the potential for treatment of numerous inflammatory skin diseases."

    In addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders (IBDs).

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.  To learn more, please visit https://ir.hoththerapeutics.com/.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Media Relations Contact:

    Makovsky

    Email:

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-confirmatory-results-from-in-vivo-model-of-ht-003-assets-as-potential-treatment-against-acne-301332322.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  4. NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

    BioLexa has been administered twice per day for 14 days to the first ten subjects within Cohort 1; The interim safety review indicates that BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed.

    "Today's announcement represents a significant milestone for Hoth," stated Robb Knie, CEO of Hoth Therapeutics. "We are very pleased by the Cohort 1 results and are proceeding as planned with submission and enrollment for Cohort 2 with atopic dermatitis patients later this year."

    About BioLexa

    BioLexa is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized, communities consisting of bacteria adhered to a surface (both biological and abiotic surfaces) and to other bacteria, and often with a protective extracellular matrix. Mature bacterial biofilms often result in chronic, recurrent infections that are difficult to treat due to the barrier effect of the biofilm that facilitates antibiotic resistance and avoiding immune system mechanisms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping the bacteria in a more susceptible state to antimicrobial therapy. This novel mechanism of action has the potential to broadly treat clinical manifestations resulting from Staphylococcal biofilm formation.

    Additional information and updates on the BioLexa clinical trial can be found by visiting www.hoththerapeutics.com and ClinicalTrials.Gov.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Media Relations Contact:

    Makovsky

    Email:

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-safety-results-from-ad001-cohort-1-of-phase-1b-clinical-trial-of-biolexa-for-the-treatment-of-atopic-dermatitis-301320779.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  5. NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease.

    The research will be led by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine. Dr. Cirrito's research has been focused on the relationship between synaptic activity and amyloid-beta metabolism in Alzheimer's disease. Amyloid-beta (Abeta) peptide accumulation within the brain extracellular space, as toxic oligomers and plaques, is strongly believed to be the primary cause of Alzheimer's disease. Dr. Yuede's research is primarily focused on the factors influencing cognitive function and brain Aß dynamics in mouse models of Alzheimer's Disease, particularly in relation to synaptic activity.

    "We are pleased to expand our work in the Alzheimer's disease space through our partnership with Dr. John Cirrito, Dr. Carla Yuede, and Washington University," said Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. "Our focus remains on bringing innovative and novel therapeutics through development to address unmet patient needs and drive shareholder value, and we are excited about the potential impact of HT-ALZ on the treatment of Alzheimer's disease and all of those affected by it."

    "The collaboration with Hoth Therapeutics is designed to explore a novel route toward the treatment of symptoms of Alzheimer's disease in pre-clinical models," said Yuede. "We are excited about the potential for new understanding in this area."   

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.  To learn more, please visit https://ir.hoththerapeutics.com/.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Media Relations Contact:

    Makovsky

    Email:

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-sponsored-research-agreement-with-washington-university-for-novel-alzheimers-therapeutic-ht-alz-301307051.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
View All Hoth Therapeutics Inc. News